MX2016010137A - Functionalised benzopyran compounds and use thereof. - Google Patents
Functionalised benzopyran compounds and use thereof.Info
- Publication number
- MX2016010137A MX2016010137A MX2016010137A MX2016010137A MX2016010137A MX 2016010137 A MX2016010137 A MX 2016010137A MX 2016010137 A MX2016010137 A MX 2016010137A MX 2016010137 A MX2016010137 A MX 2016010137A MX 2016010137 A MX2016010137 A MX 2016010137A
- Authority
- MX
- Mexico
- Prior art keywords
- functionalised
- benzopyran compounds
- present
- cancer
- compounds
- Prior art date
Links
- 150000001562 benzopyrans Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates broadly to anti-cancer agents. In particular, the present invention relates to selected benzopyran compounds, the preparation thereof, and their use in methods for treating cancer and reducing the incidence or risk of cancer recurrence.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461937368P | 2014-02-07 | 2014-02-07 | |
US201461987323P | 2014-05-01 | 2014-05-01 | |
PCT/AU2015/050040 WO2015117202A1 (en) | 2014-02-07 | 2015-02-05 | Functionalised benzopyran compounds and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016010137A true MX2016010137A (en) | 2017-02-15 |
MX368063B MX368063B (en) | 2019-09-18 |
Family
ID=53777071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010137A MX368063B (en) | 2014-02-07 | 2015-02-05 | Functionalised benzopyran compounds and use thereof. |
Country Status (25)
Country | Link |
---|---|
US (2) | US9701655B2 (en) |
EP (1) | EP2953938B1 (en) |
JP (1) | JP6570042B2 (en) |
KR (1) | KR102395543B1 (en) |
CN (2) | CN108484559A (en) |
AU (1) | AU2015213484B2 (en) |
BR (1) | BR112016018099B8 (en) |
CA (1) | CA2936012C (en) |
CL (1) | CL2016001937A1 (en) |
DK (1) | DK2953938T3 (en) |
ES (1) | ES2643407T3 (en) |
HK (1) | HK1218914A1 (en) |
IL (1) | IL241515B (en) |
LT (1) | LT2953938T (en) |
MX (1) | MX368063B (en) |
MY (1) | MY195739A (en) |
NZ (1) | NZ711603A (en) |
PH (1) | PH12016501422B1 (en) |
PL (1) | PL2953938T3 (en) |
PT (1) | PT2953938T (en) |
RU (1) | RU2676766C2 (en) |
SA (1) | SA516371583B1 (en) |
SG (2) | SG11201604490SA (en) |
SI (1) | SI2953938T1 (en) |
WO (1) | WO2015117202A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108484559A (en) * | 2014-02-07 | 2018-09-04 | 凯捷治疗有限公司 | Functionalized benzopyran compounds and application thereof |
CN116139125A (en) | 2015-02-02 | 2023-05-23 | 梅制药公司 | Combination therapy |
US10265294B2 (en) | 2016-03-31 | 2019-04-23 | Yale University | Compositions and methods for treating epithelial cancer |
CA3058492A1 (en) * | 2016-04-06 | 2017-10-12 | Noxopharm Limited | Radiotherapy improvements |
EP4005567A1 (en) | 2016-04-06 | 2022-06-01 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
CN109793730B (en) * | 2017-03-01 | 2021-03-05 | 浙江大学 | Benzopyran ring-closed chalcone structure type androgen receptor antagonist and application thereof |
EP4125870A1 (en) | 2020-03-30 | 2023-02-08 | Noxopharm Limited | Methods for the treatment of inflammation associated with infection |
AU2021286662A1 (en) * | 2020-06-11 | 2023-02-09 | Mei Pharma, Inc. | Combination therapies |
WO2023235929A1 (en) * | 2022-06-08 | 2023-12-14 | Noxopharm Limited | Functionalised benzopyran compounds and uses thereof |
CN118005594A (en) * | 2023-05-24 | 2024-05-10 | 内蒙古大学 | Synthesis of 3-hydroxybenzodihydropyran derivative and antitumor activity thereof |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3340276A (en) | 1964-04-01 | 1967-09-05 | Ciba Geigy Corp | 3, 4-diphenyl-chromans |
US3822287A (en) | 1969-04-17 | 1974-07-02 | Rexall Drug Chemical | Process for preparation of substituted 3,4-(diphenyl)chromans |
US4447622A (en) | 1981-09-22 | 1984-05-08 | Council Of Scientific And Industrial Research Rafi Marg | Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof |
BE891562A (en) | 1981-12-21 | 1982-04-16 | Council Scient Ind Res | ISOMERS 1 AND D OF D1-3, 4-TRANS-3, 4-DIARYLCHROMANES 2, 2-DISUBSTITUES AND THEIR DERIVATIVES, THEIR PREPARATION AND THEIR USE |
US5280040A (en) | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
US5451603A (en) | 1993-03-11 | 1995-09-19 | Zymogenetics, Inc. | 3,4-diarylchromans for treatment of dermatitis |
CA2208859A1 (en) | 1995-01-13 | 1996-07-18 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment |
CZ212497A3 (en) | 1995-01-13 | 1997-11-12 | Novo Nordisk As | Use of 3,4-diphenylchromans for preparing pharmaceutical preparations for treating or prophylaxis of idiopathic or physiological gynecomastia |
HUP9702244A3 (en) | 1995-01-13 | 1999-12-28 | Novo Nordisk As | Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders |
CZ211897A3 (en) | 1995-01-20 | 1997-12-17 | Novo Nordisk As | Use of 3,4-diphenylchromans for preparing pharmaceutical preparations used for dilation of vessels |
JPH10512269A (en) | 1995-01-20 | 1998-11-24 | ノボ ノルディスク アクティーゼルスカブ | Use of 3,4-diphenylchroman for the manufacture of a pharmaceutical composition for the treatment or prevention of cerebral degenerative diseases |
TW448046B (en) | 1995-01-20 | 2001-08-01 | Novo Nordisk As | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity |
US5883118A (en) | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
US5726202A (en) | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
US5747059A (en) | 1996-01-11 | 1998-05-05 | Novo Nordisk A/S | Atrophy of skin/mucous membrane |
CN1207038A (en) | 1996-01-11 | 1999-02-03 | 诺沃挪第克公司 | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms |
BR9706967A (en) | 1996-01-11 | 1999-05-04 | Novo Nordisk As | Use of compounds and process for treatment and prophylaxis of symptoms related to menopause |
US5756539A (en) | 1996-07-11 | 1998-05-26 | Novo Nordis A/S | 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders |
US5780502A (en) | 1996-07-12 | 1998-07-14 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome |
US5919817A (en) | 1996-10-28 | 1999-07-06 | Novo Nordisk A/S | Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
CA2270113A1 (en) * | 1996-10-28 | 1998-05-07 | Poul Jacobsen | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
US5925771A (en) | 1996-10-28 | 1999-07-20 | Novo Nordisk A/S | Process for the preparation of (-)-3,4-trans-diarylchromans |
AU4699897A (en) | 1996-10-28 | 1998-05-22 | Novo Nordisk A/S | Novel (-)-enantiomers of (cis)-3,4-chroman derivatives useful in the preve ntion or treatment of estrogen related diseases or syndromes |
US6043269A (en) | 1996-10-28 | 2000-03-28 | Novo Nordisk A/S | cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
WO1998033499A1 (en) | 1997-01-29 | 1998-08-06 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women |
WO1998033500A1 (en) | 1997-01-29 | 1998-08-06 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment |
US6184005B1 (en) | 1998-04-28 | 2001-02-06 | Novo Nordisk A/S | Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman |
IL142082A (en) * | 1998-09-23 | 2005-12-18 | Res Dev | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
WO2001007031A1 (en) | 1999-07-26 | 2001-02-01 | Shionogi & Co., Ltd. | Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same |
AU2001296119A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Estrogen receptor-beta ligands |
US20050119301A1 (en) | 2001-03-16 | 2005-06-02 | Alan Husband | Treatment of restenosis |
JP4256679B2 (en) | 2001-03-16 | 2009-04-22 | ノボゲン リサーチ ピーティーワイ リミテッド | How to treat restenosis |
EP1465619A1 (en) | 2002-01-14 | 2004-10-13 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
US20040167165A1 (en) | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associated with an Edg-7 receptor |
DE602004019523D1 (en) | 2003-06-04 | 2009-04-02 | Mitsubishi Gas Chemical Co | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE CHROMAN-CARBOXYLIC ACID ESTERS |
US20060167037A1 (en) * | 2003-11-19 | 2006-07-27 | Kelly Graham E | Combinational radiotherapy and chemotherapy compositions and methods |
EP2436680B1 (en) * | 2004-09-21 | 2016-05-18 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
ES2516067T3 (en) * | 2004-09-21 | 2014-10-30 | Mei Pharma, Inc. | Substituted Chroman Derivatives, Medicines and Therapy |
US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
JP4976649B2 (en) * | 2004-09-21 | 2012-07-18 | マーシャル エドワーズ,インク. | Compound |
EP1794141B1 (en) | 2004-09-21 | 2011-11-09 | Marshall Edwards, Inc. | Substituted chroman derivatives, medicaments and use in therapy |
US7528267B2 (en) | 2005-08-01 | 2009-05-05 | Girindus America, Inc. | Method for enantioselective hydrogenation of chromenes |
CA2643012A1 (en) | 2006-02-21 | 2007-08-30 | Trigen Limited | Heterocyclic compounds and their use in the treatment of cardiovascular disease |
EP2084141A4 (en) | 2006-10-30 | 2010-07-21 | Novogen Res Pty Ltd | Prevention and reversal of chemotherapy-induced peripheral neuropathy |
CN101210012B (en) | 2006-12-31 | 2011-09-14 | 南华大学 | Novel isoflavone nicotinic acid ester derivatives, preparing method and use thereof |
US20120039917A1 (en) | 2008-08-29 | 2012-02-16 | Alan James Husband | Immunomodulating activities |
WO2010045674A1 (en) | 2008-10-22 | 2010-04-29 | Novogen Research Pty Ltd | Methods for inducing programmed cell death |
AU2008230055A1 (en) | 2008-10-22 | 2010-05-06 | Novogen Research Pty Ltd | Methods for Inducing Programmed Cell Death |
WO2011115819A2 (en) | 2010-03-15 | 2011-09-22 | Genus Oncology, Llc | Small molecule inhibitors of muc1 and methods of identifying the same |
US9139592B2 (en) | 2010-06-14 | 2015-09-22 | Trt Pharma Inc. | Modulators of Nrf2 and uses thereof |
US9663484B2 (en) * | 2010-11-01 | 2017-05-30 | Mei Pharma, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
CN102153535A (en) | 2011-03-04 | 2011-08-17 | 中国海洋大学 | Benzopyranyl-3-alcohol esterified derivative serving as antineoplastic multidrug resistance inhibitor and preparation method and application of benzopyranyl-3-alcohol esterified derivative |
US20120251630A1 (en) * | 2011-03-29 | 2012-10-04 | Marshall Edwards, Inc. | Remission therapy of cancer with isoflavonoids |
US20150018566A1 (en) * | 2011-08-25 | 2015-01-15 | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy | Tubulin binding agents |
AU2013271731A1 (en) | 2012-06-07 | 2014-12-18 | Georgia State University Research Foundation, Inc. | SecA inhibitors and methods of making and using thereof |
CN103408528B (en) | 2013-08-13 | 2015-04-29 | 浙江大学 | Chroman compound, as well as preparation method and application thereof |
CN103450142B (en) | 2013-09-04 | 2015-03-25 | 浙江大学 | Chroman compound as well as extracting method and application thereof |
CN103585145A (en) | 2013-11-28 | 2014-02-19 | 常州科立信医疗器械有限公司 | Application of Artoxanthochromane in preparation of prostate cancer treatment drugs |
CN103638008B (en) | 2013-12-02 | 2015-09-16 | 刘艳娇 | The application of Artoxanthochromane in treatment skin carcinoma medicine |
CN103690525A (en) | 2013-12-02 | 2014-04-02 | 常州科立信医疗器械有限公司 | Application of Artoxanthochromane in preparation of medicine for treating tongue cancer |
CN103705503A (en) | 2013-12-04 | 2014-04-09 | 常州科立信医疗器械有限公司 | Applications of Artoxanthochromane in medicines treating breast cancer |
CN108484559A (en) * | 2014-02-07 | 2018-09-04 | 凯捷治疗有限公司 | Functionalized benzopyran compounds and application thereof |
-
2015
- 2015-02-05 CN CN201810378034.2A patent/CN108484559A/en active Pending
- 2015-02-05 WO PCT/AU2015/050040 patent/WO2015117202A1/en active Application Filing
- 2015-02-05 RU RU2016133731A patent/RU2676766C2/en active
- 2015-02-05 CA CA2936012A patent/CA2936012C/en active Active
- 2015-02-05 JP JP2016568089A patent/JP6570042B2/en active Active
- 2015-02-05 MX MX2016010137A patent/MX368063B/en active IP Right Grant
- 2015-02-05 PL PL15746211T patent/PL2953938T3/en unknown
- 2015-02-05 BR BR112016018099A patent/BR112016018099B8/en active IP Right Grant
- 2015-02-05 MY MYPI2016702471A patent/MY195739A/en unknown
- 2015-02-05 SG SG11201604490SA patent/SG11201604490SA/en unknown
- 2015-02-05 US US14/771,440 patent/US9701655B2/en active Active
- 2015-02-05 PT PT157462110T patent/PT2953938T/en unknown
- 2015-02-05 SG SG11201506988TA patent/SG11201506988TA/en unknown
- 2015-02-05 NZ NZ711603A patent/NZ711603A/en unknown
- 2015-02-05 SI SI201530099T patent/SI2953938T1/en unknown
- 2015-02-05 DK DK15746211.0T patent/DK2953938T3/en active
- 2015-02-05 AU AU2015213484A patent/AU2015213484B2/en active Active
- 2015-02-05 KR KR1020167021722A patent/KR102395543B1/en active IP Right Grant
- 2015-02-05 ES ES15746211.0T patent/ES2643407T3/en active Active
- 2015-02-05 CN CN201580002687.5A patent/CN105980372B/en active Active
- 2015-02-05 EP EP15746211.0A patent/EP2953938B1/en active Active
- 2015-02-05 LT LTEP15746211.0T patent/LT2953938T/en unknown
- 2015-09-10 IL IL241515A patent/IL241515B/en active IP Right Grant
-
2016
- 2016-06-15 HK HK16106913.3A patent/HK1218914A1/en unknown
- 2016-07-19 PH PH12016501422A patent/PH12016501422B1/en unknown
- 2016-07-31 SA SA516371583A patent/SA516371583B1/en unknown
- 2016-08-01 CL CL2016001937A patent/CL2016001937A1/en unknown
-
2017
- 2017-06-05 US US15/613,711 patent/US10370349B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501422B1 (en) | Functionalised benzopyran compounds and use thereof | |
HK1249524A1 (en) | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers | |
EP3166640A4 (en) | Combination therapy compositions and methods for treating cancers | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
IL253979B (en) | Methods, compositions, and kits for treatment of cancer | |
TW201613648A (en) | Compounds and compositions for immunotherapy | |
MA39906A (en) | Combination therapies for the treatment of cancer | |
EP3222278A4 (en) | Use of azelnidipine in preparing medicinal composition for treating cancers | |
EP3169363A4 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2016006726A (en) | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy. | |
IL276733A (en) | Use of eribulin in the treatment of cancer | |
MX2016016881A (en) | Antibodies binding axl. | |
MX2016009590A (en) | Apilimod compositions and methods for using same. | |
MX2017006015A (en) | Apilimod for use in the treatment of renal cancer. | |
EP3200815A4 (en) | Methods and compositions for treating cancer | |
MX2018000715A (en) | Methods for treating cancer using apilimod. | |
MX2019013808A (en) | Compounds for treatment of cancer. | |
MX2017006026A (en) | Apilimod for use in the treatment of colorectal cancer. | |
PH12016501838A1 (en) | Compounds and their methods of use | |
EP3169333A4 (en) | Methods and compositions for enhancing cancer therapy | |
MX2017009608A (en) | Anti-cancer compounds. | |
IL249860A0 (en) | Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer | |
EP3160591A4 (en) | Compositions and methods for treating cancer | |
GB2546703A (en) | Compounds | |
ZA201403006B (en) | Composition for use in treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |